

Executive Summary Of the Minutes Board of Directors' Meeting January 31-February 1, 2013

Proceedings:

Meeting Called to Order at 8:30 a.m. (local time) by Chair, Daniel Arndt. A quorum was noted.

Minutes from September 27-28, 2012 board meeting were reviewed and approved with no substantive changes.

Comments from the Board Chair: New board members were introduced - Lynn Abrahamsen, Michael Davenport, David Porter, MD and Robert Baitty.

Update from Chief Executive Officer:

- Patient Ethnicity – Recent analysis shows higher diversity exists among donors than recipients-particularly among Hispanic ethnicity. NMDP discovered that patient information is often completed before patient arrives at transplant center.
- Facilities Plan - Final three options were reviewed. Key terms for a 15-year lease were discussed. The Executive Committee was given approval by the board to move forward with lease negotiations.
- Executive search firm retained for selection of candidates to interview for CFO position- on target to fill position by July 1, 2013.
- Donor Compensation - Congressman Young and Representative Matsui plan to introduce a Bill amending the *National Organ Transplant Act* to define PBSC as marrow for the purposes of the Act to the 113th Congress.
- Compliance Oversight Committee met in Minneapolis on December 21, 2012. Presentations from the Office of General Counsel, Regulatory Compliance, Internal Audit, Risk Management, IT Security, Operations and Human Resources were provided. No material compliance deficiencies were identified.

Chief Financial Officer's Report – Financial summary as of December 31, 2012 was reviewed.

- NMDP reserves total \$62 million.

External Audit – The Board approved the external audit report for FY 2012 prepared by Deloitte; which was reviewed in detail and recommended to the board for approval by the Audit Committee during their meeting on January 4, 2013. No significant findings were noted.

Charter Revisions - Audit Committee; Cord Blood Advisory Group; Council Advisory Group; Donor & Patient Safety Monitoring Advisory Group; and Histocompatibility Advisory Group were reviewed and unanimously approved.

Network Approvals - Recommendations from the Membership Review Committee for *network center* changes since the Sept. 27-28, 2012 board meeting were reviewed and unanimously approved.

Phoenix Initiative – Release 2 *go-live* date scheduled for February 4, 2013 has been tentatively rescheduled for March 18, 2013. Components include: Case Management, Traxis®, EmTrax™ and Oracle for Order Orchestration.

Risk Management Team provided an overview of the risk management function at the NMDP. Current risks identified are: Medical Practice, Regulatory Compliance and Member Performance.

Strategic Planning – FY 2014 Strategic Planning Process was reviewed.

- Current need is approximately 12,000 patients per year.
- NMDP continues to focus on providing a cell source, improving the quality of the cell source, and improving outcomes.

HRSA reported that NMDP has exceeded the goals set by HRSA and the Office of Management and Budget in 2004. Revised goals through FY 2020 are in development.

Next meeting - Thursday & Friday, June 6-7, 2013 – Henderson, Nevada

Meeting Adjourned